Tendencias Ahora
Listas Principales
Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.
¿Ya eres miembro? Iniciar sesión
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States.... Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Mostrar más
- BLA and MAA submission for apitegromab in SMA on track for 1Q 2025; if approved, U.S. launch expected in 4Q 2025 - Initiating Phase 2 OPAL clinical trial in SMA patients under two years old in...
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other...
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other...
- Reported positive topline data from pivotal Phase 3 SAPPHIRE trial evaluating apitegromab in patients with Spinal Muscular Atrophy (SMA), achieving primary endpoint - On track to submit a U.S...
- Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin - Data support that Scholar Rock’s unique approach to selective myostatin...
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious...
Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
---|---|---|---|---|---|---|---|---|
1 | -4.11 | -9.21524663677 | 44.6 | 46.07 | 39.79 | 938231 | 42.12473556 | CS |
4 | -0.46 | -1.12332112332 | 40.95 | 46.17 | 39.79 | 981950 | 43.15807804 | CS |
12 | 11.18 | 38.1439781644 | 29.31 | 46.185 | 25.75 | 1061606 | 35.97027864 | CS |
26 | 32.55 | 409.949622166 | 7.94 | 46.185 | 6.76 | 1373216 | 27.10201793 | CS |
52 | 24.3 | 150.092649784 | 16.19 | 46.185 | 6.76 | 1117773 | 21.81318805 | CS |
156 | 19.36 | 91.6232844297 | 21.13 | 46.185 | 4.325 | 729150 | 15.750537 | CS |
260 | 27.55 | 212.905718702 | 12.94 | 70 | 4.325 | 609987 | 21.41396295 | CS |
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones